vTv TherapeuticsFRA:5VT0 +0.67%35 Net Current Asset Value is €19.75 as of Mar. 2026, which is 100% below its 10-year median of 2.65. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €6,725.03. Among 943 Biotechnology companies, vTv Therapeutics ranks better than 84.31% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
vTv Therapeutics's net current asset value per share for the quarter that ended in Mar. 2026 was €19.75.
The historical rank and industry rank for vTv Therapeutics's Net Current Asset Value or its related term are showing as below:
FRA:5VT0'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.3 Med: 2.65 Max: 14.56
Current: 1.54
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of vTv Therapeutics was 14.56. The lowest was 1.30. And the median was 2.65.
FRA:5VT0's Price-to-Net-Current-Asset-Value is ranked better than 84.31% of 943
companies
in the Biotechnology industry
Industry Median: 4.95
vs FRA:5VT0: 1.54
vTv Therapeutics (FRA:5VT0) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
vTv Therapeutics Net Current Asset Value Related Terms
vTv Therapeutics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5VT0 vs SMNR, CNTB, ENLV: Net Current Asset Value Comparison
For the Biotechnology subindustry, vTv Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €19.75 mean?
vTv Therapeutics (FRA:5VT0) has a Net Current Asset Value of €19.75 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on vTv Therapeutics and its competitors. This is 645% above median its historical median of 2.65. Over the past decade, vTv Therapeutics' Net Current Asset Value has ranged from 1.30 to 14.56. According to the industry distribution chart, vTv Therapeutics ranks #148 out of 943 companies in the Biotechnology industry, placing it in the top 15.7%.
Is vTv Therapeutics' Net Current Asset Value too high?
vTv Therapeutics' current Net Current Asset Value of €19.75 is 645% above median its 10-year median of 2.65. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 14.56. Based on the distribution chart, vTv Therapeutics ranks #148 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Net Current Asset Value compare to SMNR and CNTB?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #148 out of 943 companies for Net Current Asset Value. This places vTv Therapeutics in the top 16% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.95. Historically, vTv Therapeutics' own Net Current Asset Value has ranged from 1.30 to 14.56 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.95, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on vTv Therapeutics and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. vTv Therapeutics's current Net Current Asset Value is €19.75, which is 645% above median its own 10-year median of 2.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Net Current Asset Value of €19.75. The stock's GF Value™ is €6,725.03, compared to a current price of €30.20 — trading 99.6% below its estimated fair value. The current Net Current Asset Value is €19.75, which is 645% above median its 10-year median of 2.65. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Net Current Asset Value is €19.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?
Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued.
The current stock price of €30.20 is trading 99.6% below its estimated GF Value™ of €6,725.03.
Key valuation signals for FRA:5VT0:
Net Current Asset Value: €19.75 (645% above median its 10-year median of 2.65)
GF Value™: €6,725.03 vs. price of €30.20 (99.6% below fair value)
No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score
Get the complete analysis for FRA:5VT0
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VT0 has been successfully added to your 
